11.09.2020 • NewsAbbVie

AbbVie and I-Mab in Cancer Collaboration

US biopharma AbbVie has signed a global collaboration agreement with China’s I-Mab to develop and commercialize lemzoparlimab – also known as TJC4 – an anti-CD47 monoclonal antibody for treating multiple cancers. The companies can also potentially expand the collaboration to include other therapies.

“The addition of I-Mab's novel CD47 programs complements our global clinical strategy in hematology and immuno-oncology,” said Thomas Hudson, AbbVie’s senior vice president of R&D and chief scientific officer. In a recent phase 1 clinical trial, lemzoparlimab showed promising results relating to drug safety and a more favorable pharmacokinetics profile in cancer patients.

Under the terms of the agreement, AbbVie will pay $180 million upfront to I-Mab for exclusive global rights (excluding greater China) to lemzoparlimab as well as a milestone payment of $20 million for the positive results from the Phase 1 trial. The Chinese biotech will be responsible for developing and commercializing lemzoparlimab in mainland China, Macau and Hong Kong.

I-Mab will also be entitled to earn up to $840 million in future success-based clinical and development milestones as well as up to $900 million in commercial milestones and tiered low-to-mid-teen royalties on net sales.

 

Author: Elaine Burridge, Freelance Journalist

AbbVie has signed a global collaboration agreement with China’s I-Mab to...
AbbVie has signed a global collaboration agreement with China’s I-Mab to commercialize lemzoparlimab – also known as TJC4 – an anti-CD47 monoclonal antibody for treating multiple cancers. The companies can also potentially expand the collaboration to include other therapies. (c) AbbVie

Company

Logo:

AbbVie Inc.


North Chicago, Illinois
US

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.